Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN-725 and Dositinib in EGFR-mutant NSCLC
NCT07362940Phase 2Recruiting
- Sponsor
- Genuine Biotech
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azvudine in non-small cell lung cancer (NSCLC), sponsored by Genuine Biotech. Started Nov 2025; status: recruiting.
02
Drugs
azvudine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07362940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362940.